Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785268 | 0.85 | HTR2B (0.59) | RAB9AGAATLR7MAPTLMNA | |
| SCHEMBL3412110 | 0.85 | ALDH1A1 (0.71) | RAB9AGAATLR7MAPTLMNA | |
| SCHEMBL6821162 | 0.85 | RAB9A (0.68) | RAB9AGAATLR7MAPTLMNA | |
| SCHEMBL16310305 | 0.83 | TLR7 (0.57) | RAB9AGAATLR7LMNAHTR2B | |
| SCHEMBL999473 | 0.83 | HDAC1 (0.69) | RAB9AGAALMNAHTR2BKDM4E | |
| SCHEMBL13078466 | 0.83 | RAB9A (0.70) | RAB9AGAATLR7MAPTLMNA | |
| Hydrochloric Acid SCHEMBL6821165 | 0.83 | ALDH1A1 (0.69) | RAB9AGAATLR7MAPTLMNA | |
| SCHEMBL10334420 | 0.83 | ALDH1A1 (0.73) | RAB9AGAATLR7L3MBTL1HTR2B | |
| SCHEMBL168519 | 0.83 | HTR2B (0.66) | RAB9AGAATLR7MAPTLMNA | |
| SCHEMBL6202834 | 0.83 | HPGD (0.64) | TLR7MAPTLMNAHTR2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096111-A1 | PYRAZOLES AND USE THEREOF AS DRUGS | Japan Tobacco Inc. (JP) | 2009-09-02 | — | — | EP | claimed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | claimed |
| US-9982015-B2 | Cyclin based inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170218018-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-9376465-B2 | Cyclin based inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150011730-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-08 | — | — | US | disclosed |
| US-20140296484-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA (US) | 2014-10-02 | — | — | US | disclosed |
| US-20130289240-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA | 2013-10-31 | — | — | US | disclosed |
| EP-2278969-A2 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2010011375-A2 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-2096111-A1 | PYRAZOLES AND USE THEREOF AS DRUGS | Japan Tobacco Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011730-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | CDK4, CDK2, CDK8 | RAB9A 4074/4885GAA 3372/4885TLR7 2492/4885 |
| US-20130289240-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | CDK4, CDK2, CDK8 | RAB9A 4074/4885GAA 3372/4885TLR7 2492/4885 |
| US-20170218018-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | CDK4, CDK2, CDK8 | RAB9A 4074/4885GAA 3372/4885TLR7 2492/4885 |
| US-20140296484-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | CDK4, CDK2, CDK8 | RAB9A 4074/4885GAA 3372/4885TLR7 2492/4885 |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | PYGL, GYS2, G6PC1 | RAB9A 4343/4885GAA 81/4885TLR7 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.